Cargando…
Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population
Serological assays have been used in seroprevalence studies to inform the dynamics of COVID-19. Lateral flow immunoassay (LFIA) tests are a very practical technology to use for this objective; however, one of their challenges may be variable diagnostic performance. Given the numerous available LFIA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237462/ https://www.ncbi.nlm.nih.gov/pubmed/37267241 http://dx.doi.org/10.1371/journal.pgph.0001555 |
_version_ | 1785053160977465344 |
---|---|
author | Calderon-Flores, Rodrigo Caceres-Cardenas, Guillermo Alí, Karla De Vos, Margaretha Emperador, Devy Cáceres, Tatiana Eca, Anika Villa-Castillo, Luz Albertini, Audrey Sacks, Jilian A. Ugarte-Gil, Cesar |
author_facet | Calderon-Flores, Rodrigo Caceres-Cardenas, Guillermo Alí, Karla De Vos, Margaretha Emperador, Devy Cáceres, Tatiana Eca, Anika Villa-Castillo, Luz Albertini, Audrey Sacks, Jilian A. Ugarte-Gil, Cesar |
author_sort | Calderon-Flores, Rodrigo |
collection | PubMed |
description | Serological assays have been used in seroprevalence studies to inform the dynamics of COVID-19. Lateral flow immunoassay (LFIA) tests are a very practical technology to use for this objective; however, one of their challenges may be variable diagnostic performance. Given the numerous available LFIA tests, evaluation of their accuracy is critical before real-world implementation. We performed a retrospective diagnostic evaluation study to independently determine the diagnostic accuracy of 4 different antibody-detection LFIA tests: Now Check (Bionote), CareStart (Access bio), Covid-19 BSS (Biosynex) and OnSite (CTK Biotech). The sample panel was comprised of specimens collected and stored in biobanks; specifically, specimens that were RT-PCR positive for SARS-CoV-2 collected at various times throughout the COVID-19 disease course and those that were collected before the pandemic, during 2018 or earlier, from individuals with upper respiratory symptoms but were negative for tuberculosis. Clinical performance (sensitivity and specificity) was analyzed overall, and subset across individual antibody isotypes, and days from symptoms onset. A very high specificity (98% - 100%) was found for all four tests. Overall sensitivity was variable, ranging from 29% [95% CI: 21%-39%] to 64% [95% CI: 54%-73%]. When considering detection of IgM only, the highest sensitivity was 42% [95% CI: 32%-52%], compared to 57% [95% CI: 47%-66%] for IgG only. When the analysis was restricted to at least 15 days since symptom onset, across any isotype, the sensitivity reached 90% for all four brands. All four LFIA tests proved effective for identifying COVID-19 antibodies when two conditions were met: 1) at least 15 days have elapsed since symptom onset and 2) a sample is considered positive when either IgM or IgG is present. With these considerations, the use of this assays could help in seroprevalence studies or further exploration of its potential uses. |
format | Online Article Text |
id | pubmed-10237462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-102374622023-06-03 Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population Calderon-Flores, Rodrigo Caceres-Cardenas, Guillermo Alí, Karla De Vos, Margaretha Emperador, Devy Cáceres, Tatiana Eca, Anika Villa-Castillo, Luz Albertini, Audrey Sacks, Jilian A. Ugarte-Gil, Cesar PLOS Glob Public Health Research Article Serological assays have been used in seroprevalence studies to inform the dynamics of COVID-19. Lateral flow immunoassay (LFIA) tests are a very practical technology to use for this objective; however, one of their challenges may be variable diagnostic performance. Given the numerous available LFIA tests, evaluation of their accuracy is critical before real-world implementation. We performed a retrospective diagnostic evaluation study to independently determine the diagnostic accuracy of 4 different antibody-detection LFIA tests: Now Check (Bionote), CareStart (Access bio), Covid-19 BSS (Biosynex) and OnSite (CTK Biotech). The sample panel was comprised of specimens collected and stored in biobanks; specifically, specimens that were RT-PCR positive for SARS-CoV-2 collected at various times throughout the COVID-19 disease course and those that were collected before the pandemic, during 2018 or earlier, from individuals with upper respiratory symptoms but were negative for tuberculosis. Clinical performance (sensitivity and specificity) was analyzed overall, and subset across individual antibody isotypes, and days from symptoms onset. A very high specificity (98% - 100%) was found for all four tests. Overall sensitivity was variable, ranging from 29% [95% CI: 21%-39%] to 64% [95% CI: 54%-73%]. When considering detection of IgM only, the highest sensitivity was 42% [95% CI: 32%-52%], compared to 57% [95% CI: 47%-66%] for IgG only. When the analysis was restricted to at least 15 days since symptom onset, across any isotype, the sensitivity reached 90% for all four brands. All four LFIA tests proved effective for identifying COVID-19 antibodies when two conditions were met: 1) at least 15 days have elapsed since symptom onset and 2) a sample is considered positive when either IgM or IgG is present. With these considerations, the use of this assays could help in seroprevalence studies or further exploration of its potential uses. Public Library of Science 2023-06-02 /pmc/articles/PMC10237462/ /pubmed/37267241 http://dx.doi.org/10.1371/journal.pgph.0001555 Text en © 2023 Calderon-Flores et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Calderon-Flores, Rodrigo Caceres-Cardenas, Guillermo Alí, Karla De Vos, Margaretha Emperador, Devy Cáceres, Tatiana Eca, Anika Villa-Castillo, Luz Albertini, Audrey Sacks, Jilian A. Ugarte-Gil, Cesar Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population |
title | Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population |
title_full | Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population |
title_fullStr | Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population |
title_full_unstemmed | Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population |
title_short | Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population |
title_sort | diagnostic performance of four lateral flow immunoassays for covid-19 antibodies in peruvian population |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237462/ https://www.ncbi.nlm.nih.gov/pubmed/37267241 http://dx.doi.org/10.1371/journal.pgph.0001555 |
work_keys_str_mv | AT calderonfloresrodrigo diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT cacerescardenasguillermo diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT alikarla diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT devosmargaretha diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT emperadordevy diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT cacerestatiana diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT ecaanika diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT villacastilloluz diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT albertiniaudrey diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT sacksjiliana diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation AT ugartegilcesar diagnosticperformanceoffourlateralflowimmunoassaysforcovid19antibodiesinperuvianpopulation |